(Q38118313)

29 August 2017

Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response (English)

1 reference

inflammatory bowel diseases

29 August 2017

1 reference

Gary R Lichtenstein

1

1 reference

29 August 2017

1 July 2013

1 reference

Therapeutic Advances in Gastroenterology

29 August 2017

1 reference

29 August 2017

6

1 reference

29 August 2017

4

1 reference

29 August 2017

269-293

1 reference

Therapeutic drug monitoring of biologics for inflammatory bowel disease

29 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Clinical pharmacokinetics of therapeutic monoclonal antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Biologic targeting in the treatment of inflammatory bowel diseases.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Certolizumab pegol for the treatment of Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Trends in hospitalization rates for inflammatory bowel disease in the United States

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Elimination mechanisms of therapeutic monoclonal antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Infliximab for induction and maintenance therapy for ulcerative colitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Fc receptors and their interactions with immunoglobulins

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Therapeutic drug monitoring

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Disease activity courses in a regional cohort of Crohn's disease patients.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Infliximab, azathioprine, or combination therapy for Crohn's disease

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3667472

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756283X13479826

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756283X13479826

A Theoretical Model of γ-Globulin Catabolism

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756283X13479826

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

21 January 2018

1 reference

12 December 2020

Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study

1 reference

12 December 2020

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

1 reference

12 December 2020

A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2012May 19-22, 2012 • San Diego, CaliforniaSpecial Reporting on:• Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Dise

1 reference

12 December 2020

Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease

1 reference

12 December 2020

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

12 December 2020

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

12 December 2020

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

1 reference

12 December 2020

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X13479826

1 reference

29 August 2017

1 reference

PMC publication ID

3667472

29 August 2017

PubMed publication ID

23814608

1 reference

PMC publication ID

3667472